{
    "8df0abf0-3994-38c1-be5e-d4331499e06c": {
        "uuid": "8df0abf0-3994-38c1-be5e-d4331499e06c",
        "title": "Nasdaq Bear Market: 4 Exceptional Growth Stocks You'll Regret Not Buying on the Dip",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/8df0abf0-3994-38c1-be5e-d4331499e06c/nasdaq-bear-market%3A-4.html",
        "providerPublishTime": 1653728760,
        "type": "STORY"
    },
    "25e77040-bb4c-3b53-a9fa-144f0e2995ab": {
        "uuid": "25e77040-bb4c-3b53-a9fa-144f0e2995ab",
        "title": "Why Novavax Is Up More Than 18% Today",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/25e77040-bb4c-3b53-a9fa-144f0e2995ab/why-novavax-is-up-more-than.html",
        "providerPublishTime": 1653677460,
        "type": "STORY"
    },
    "019a1156-44e5-3518-b43c-696d2cb638b1": {
        "uuid": "019a1156-44e5-3518-b43c-696d2cb638b1",
        "title": "White House steps up effort to provide antiviral access to more Americans as cases start to stabilize in Northeast",
        "publisher": "MarketWatch",
        "link": "https://finance.yahoo.com/m/019a1156-44e5-3518-b43c-696d2cb638b1/white-house-steps-up-effort.html",
        "providerPublishTime": 1653661380,
        "type": "STORY"
    },
    "bb501a0f-205d-3b71-bd74-b7fbd3372ef2": {
        "uuid": "bb501a0f-205d-3b71-bd74-b7fbd3372ef2",
        "title": "The FDA\u2019s decision on the Novavax COVID-19 vaccine could come in weeks",
        "publisher": "MarketWatch",
        "link": "https://finance.yahoo.com/m/bb501a0f-205d-3b71-bd74-b7fbd3372ef2/the-fda%E2%80%99s-decision-on-the.html",
        "providerPublishTime": 1653650460,
        "type": "STORY"
    },
    "98b6ff3d-feb4-3cd8-aa14-c8b6c83b9c0d": {
        "uuid": "98b6ff3d-feb4-3cd8-aa14-c8b6c83b9c0d",
        "title": "Why Wall Street Thinks Novavax Is a No-Brainer Stock to Buy Right Now",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/98b6ff3d-feb4-3cd8-aa14-c8b6c83b9c0d/why-wall-street-thinks.html",
        "providerPublishTime": 1653645300,
        "type": "STORY"
    },
    "25394926-0cc0-3662-a485-30cd429166cb": {
        "uuid": "25394926-0cc0-3662-a485-30cd429166cb",
        "title": "Why Novavax Was Tumbling by 12% This Week",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/25394926-0cc0-3662-a485-30cd429166cb/why-novavax-was-tumbling-by.html",
        "providerPublishTime": 1653606793,
        "type": "STORY"
    },
    "e0359674-6102-3d4e-ba33-c889615866c5": {
        "uuid": "e0359674-6102-3d4e-ba33-c889615866c5",
        "title": "Better Buy Ahead of FDA Meetings: Moderna vs. Novavax",
        "publisher": "Motley Fool",
        "link": "https://finance.yahoo.com/m/e0359674-6102-3d4e-ba33-c889615866c5/better-buy-ahead-of-fda.html",
        "providerPublishTime": 1653472800,
        "type": "STORY"
    },
    "7c7600a5-1e38-331d-861e-2781c228bb34": {
        "uuid": "7c7600a5-1e38-331d-861e-2781c228bb34",
        "title": "Is Novavax Stock A Sell After Its First Covid Vaccine Quarter Misses Projections?",
        "publisher": "Investor's Business Daily",
        "link": "https://finance.yahoo.com/m/7c7600a5-1e38-331d-861e-2781c228bb34/is-novavax-stock-a-sell-after.html",
        "providerPublishTime": 1653408087,
        "type": "STORY"
    }
}